James Bradner
MD
President of Research
👥Biography 个人简介
James Bradner developed JQ1 — the seminal BET bromodomain inhibitor that demonstrated proof-of-concept for targeting the BRD4-MYC transcriptional axis in cancer. His open-source approach to sharing JQ1 with the research community and his work demonstrating BET inhibitor activity in NUT carcinoma, multiple myeloma, and other MYC-driven cancers catalyzed an entire field of epigenetic drug discovery targeting bromodomain and transcriptional regulatory proteins.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 James Bradner 的研究动态
Follow James Bradner's research updates
留下邮箱，当我们发布与 James Bradner（Novartis Institutes for Biomedical Research）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment